I do not know the percentage of the deal offhand, but you can get a rough figure by doing the math from the latest corporate presentation that provided the potential revenue figures to Par and IPCI.
More importantly than the revenue and profitability in my opinion is the market perception and the initial validation of their drug delivery technology. They have applied this proprietary technology to the other ANDAs as well. The potential for future lucrative partnerships are just on the horizon now. It's possible that the may partner with Par for the other drugs as well, maybe that's what Par was waiting for with IPCI. Maybe they were waiting for the first approval before working on the deals for the other drugs.
I saw that presentation also where the slide shows a potential revenue range but that appears to be split between both IPCI and Par. Even assuming 50/50 that should equate to substantial income for IPCI and a big jump in market cap. And yes, it increases the optionality of the rest of their pipeline in my view!!!!